trump and glp-1 President Donald announces an agreement with drugmakers Novo Nordisk Eli Lilly to lower the cost of their weight loss drugs Wegovy and Zepbound, a move that could make them more GLP-1 price reduction: President Trump

The CV safety of a lower dose of liraglutide (1.8 mg, Victoza, Novo Nordisk) in people with T2D was established in the Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results (LEADER) study, showing a 13% reduction in major CV events over an average of 3.8 years [44]

However, its cosmetic status also means it is not held to the same efficacy-proof standard as an approved drug, and higher-concentration or injectable forms marketed for research use are not approved for human therapeutic use and fall into a legal grey area that varies by jurisdiction

Medicare coverage and eligibility rules are subject to change

PMID: 25857584